Condition
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Terminated2
Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04727151Phase 1Terminated
TAC T-cells for the Treatment of HER2-positive Solid Tumors
NCT05207722Phase 1TerminatedPrimary
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
NCT06650332Phase 1RecruitingPrimary
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
NCT05141747Phase 2Unknown
A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.
Showing all 4 trials